A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?
- 262 Downloads
The therapeutic potential of epi-immunotherapeutic anticancer agent RRx-001 in cancer has been validated with preclinical and clinical studies, since RRx-001 has successfully completed a phase 1 trial and multiple single-agent and combination phase 2 trials with preliminary evidence of promising activity are underway. Previous experimental work has implicated diverse anticancer mechanisms such as oxidative stress, ATP and NADPH depletion, anti-angiogenesis and epigenetic modulation in the overall antitumor effect of RRx-001. The hypothesis of this study was that the RRx-001 red blood cells are the essential and de facto intermediaries responsible for the reprograming of tumor behavior via transfer of their intracellular and membrane contents. To test this hypothesis, and thereby resolve the “black box” incompleteness in the continuity of the mechanism, the fate of red blood cells incubated with RRx-001 was explored in vitro and in vivo both in healthy animals and in tumor-bearing mice. The collective results establish that RRx-001-derivatized red blood cells are the critical “missing links” to explain the specificity and anticancer activity of RRx-001, including its immunomodulatory effects on tumor-associated macrophages. These experimental results delineate a novel erythrocyte-based mechanism without precedent in the annals of oncology and open the door to rational combination strategies with RRx-001 both in cancer therapy and beyond, particularly in disease states that affect red blood cell and vascular function such as malaria, leishmaniasis, sickle-cell disease and hemorrhagic shock.
KeywordsAnticancer mechanisms Red blood cell Immunomodulation Anti-angiogenesis Epigenetic modulation RRx-001
This work was supported by EpicentRx.
All authors contributed to all stages of work behind this manuscript: idea conception, design and execution of the studies, analysis, drafting, writing and editing of the manuscript.
Compliance with ethical standards
Conflict of interest
Authors J. S. and B. O. are employees of EpicentRx. The remaining authors declare no conflicts of interest.
- 9.Fens MH, Larkin SK, Morris CR, Fitch B, Scicinski J, Oronsky B, Kuypers FA. NO or no NO, increased reduction of nitrite to nitric oxide by modified red blood cells ASH abstract Dec 2011.Google Scholar
- 10.D’Agnillo F, Alayash AI. Interactions of hemoglobin with hydrogen peroxide alters thiol levels and course of endothelial cell death. Am J Physiol Heart Circ Physiol. 2000;279:1880–9.Google Scholar
- 16.Reid T, Dad S, Korn R, Oronsky B, Knox S, Scicinski J. Two case reports of resensitization to previous chemotherapy with the novel hypoxia-activated hypomethylating anticancer agent RRx-001 in metastatic colorectal cancer patients. Case Rep Oncol. 2014;7(1):79–85.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.EpicentRx, Inc unpublished data.Google Scholar
- 19.Cabrales P, Oronsky B, Scicinski J. RRx-001 inhibits glucose erythrocyte and tumor glucose 6-phosphate dehydrogenase, abstract 1420: AACR annual meeting, 2014; 5–9 April 2014, San Diego, CA.Google Scholar
- 21.Scicinski J, Oronsky B, Ning S, Minchinton A, Knox S. RRx-001 modulates intratumor blood flow in SCCVII and U87 tumors, cancer research: 15, April 2012; volume 72, issue 8, supplement 1 (4371) Proceedings: AACR 103rd annual meeting, 2012; 31 March to 4 April, 2012; Chicago, IL.Google Scholar
- 22.Scicinski J, Oronsky B, Ning S, Minchinton A, Knox S. Antivascular activity of RRx-001 in SCCVII and U87 tumors, 15th International symposium on anti-angiogenic therapy, La Jolla, 31 Jan to 2 Feb, 2013.Google Scholar